Cardinal Health, Inc. is a global healthcare services and products company that reported $222.6 billion in revenue for fiscal year 2025 while absorbing the loss of a $38.1 billion customer contract—17% of its annual sales—and raising earnings guidance. Founded in 1971 by Robert D. Walter as a food wholesaler in Dublin, Ohio, the company pivoted to pharmaceutical distribution in 1979 and has grown into one of three companies controlling over 90% of the U.S. pharmaceutical wholesale market. Cardinal Health now employs approximately 48,000-57,700 people globally and trades on the NYSE under ticker CAH with a market capitalization of approximately $48.2 billion.
Cardinal Health: Key Facts
- Founded: 1971 in Dublin, Ohio
- Headquarters: Dublin, Ohio, United States
- CEO: Jason M. Hollar (since September 2022)
- FY2025 Revenue: $222.6 billion
- FY2025 Net Earnings: $1.57 billion (up 83% YoY)
- FY2025 Non-GAAP EPS: $8.24 (up 9% YoY)
- Employees: Approximately 48,000-57,700
- Market Cap: Approximately $48.2 billion
- Primary Business: Pharmaceutical wholesale distribution
- Key Joint Venture: Red Oak Sourcing with CVS Health
How Does Cardinal Health Make Money?
Cardinal Health generates revenue through three primary mechanisms. The Pharmaceutical and Specialty Solutions segment, which accounts for 92% of revenue, distributes branded, generic, and specialty pharmaceutical products to over 100,000 pharmacy and provider locations daily. The segment generated $204.6 billion in fiscal 2025 revenue and $2.26 billion in segment profit—a razor-thin 1.10% margin that is standard for pharmaceutical wholesale. Revenue comes from product sales, distribution fees, data reporting services, and manufacturer rebates.
The Global Medical Products and Distribution segment (6% of revenue, $12.6 billion) manufactures and distributes medical and surgical products including gloves, syringes, wound care, and surgical apparel. The 'Other' businesses (2% of revenue, $5.4 billion) include Nuclear and Precision Health Solutions (radiopharmaceuticals), at-Home Solutions (direct-to-patient medical supplies), and OptiFreight Logistics—these are the company's highest-margin operations at 9.59% segment profit margin, nearly 10x the core distribution margin.
Who Founded Cardinal Health and When?
Cardinal Health was founded in 1971 by Robert D. Walter, a 26-year-old Harvard MBA graduate who borrowed $1.3 million to acquire the food-distribution division of Consolidated Foods in a leveraged buyout. Walter named the company Cardinal Foods after Ohio's state bird and set about building a regional food distribution business. By 1980, he had grown the company tenfold but reached a strategic dead end as the food distribution industry consolidated.
In 1979, Walter pivoted to pharmaceutical distribution by acquiring Bailey Drug Co. in Zanesville, Ohio. He executed a rapid series of acquisitions throughout the 1980s, took the company public in 1983, and changed the name to Cardinal Health in 1994. Under his 33-year tenure as CEO, Cardinal grew from a small food distributor into a $50+ billion healthcare conglomerate through dozens of strategic acquisitions including Allegiance Healthcare ($4.4 billion, 1999) and the Patient Recovery business from Medtronic ($6.1 billion, 2017).
What Is Cardinal Health's Competitive Advantage?
Cardinal Health's most defensible competitive moat is its position as one of three companies controlling over 90% of the U.S. pharmaceutical wholesale market. This oligopoly structure creates three specific advantages: scale purchasing power through the Red Oak Sourcing joint venture with CVS Health (one of the largest generic drug buyers in the U.S.), a national distribution infrastructure serving over 100,000 locations daily that would cost billions to replicate, and the nation's largest nuclear pharmacy network with significant regulatory barriers to entry.
The Red Oak Sourcing joint venture, established in 2014, negotiates generic supply contracts for over 9,000 CVS retail locations and Cardinal Health's entire distribution network. The 10-year initial term provides stability that competitors cannot match. The at-Home Solutions and OptiFreight Logistics businesses add further differentiation with higher margins and recurring revenue streams.
How Has Cardinal Health's Revenue Grown Over Time?
Cardinal Health's revenue trajectory reflects its acquisition-driven growth strategy and the dynamics of pharmaceutical wholesale. The company reported $181.3 billion in fiscal 2022, $205.0 billion in fiscal 2023, $226.8 billion in fiscal 2024, and $222.6 billion in fiscal 2025. The fiscal 2025 decline reflects the OptumRx contract expiration ($38.1 billion), while the underlying business grew 18% excluding this impact.
The revenue story is one of enormous scale with minimal margin. The company generates over $200 billion in annual revenue but only $2.8 billion in non-GAAP operating earnings—a 1.25% margin. This margin structure is inherent to pharmaceutical wholesale and explains why the company trades at just 0.22x sales. The strategic challenge is whether specialty care acquisitions can generate higher-margin revenues that improve overall profitability.
Cardinal Health Business Model Explained
Cardinal Health operates a healthcare supply chain intermediary model that functions on razor-thin margins but enormous volume. The company purchases pharmaceutical products from manufacturers, holds inventory in national distribution centers, and sells to pharmacies, hospitals, and other healthcare providers. Gross margin was just 3.67% ($8.17 billion on $222.6 billion in revenue) in fiscal 2025.
The business model has three defining characteristics. First, extreme customer concentration: OptumRx represented 17% of revenue before its departure, and CVS Health remains critical. Second, generic drug pricing volatility: generic prices generally decline over time, compressing distributor margins, though price appreciation events can provide temporary profit boosts. Third, value-added services: distributors earn fees for data reporting, inventory management, and logistics services that supplement product margins. The model's sustainability depends on flawless execution at enormous scale.
Cardinal Health Key Acquisitions
Cardinal Health's most recent acquisitions reflect its strategic pivot toward specialty care services. The company acquired Integrated Oncology Network (oncology), a 71% stake in GI Alliance (gastroenterology), Advanced Diabetes Supply Group ($1.1 billion, diabetes), and Solaris Health (urology) to build a physician-facing services platform. These acquisitions are designed to create integrated care networks with higher margins than core distribution.
Historically, the company's most significant acquisitions include Allegiance Healthcare ($4.4 billion, 1999), which established the medical products business; the Patient Recovery business from Medtronic ($6.1 billion, 2017); and Bailey Drug Co. (1979), which launched the pharmaceutical distribution business. The Red Oak Sourcing joint venture with CVS Health (2014) is not an acquisition but a strategic partnership that created the largest generic pharmaceutical sourcing entity in the United States.
What Are the Biggest Risks Facing Cardinal Health?
The biggest risk is the combination of customer concentration and razor-thin margins. The OptumRx loss proved that a single customer departure can remove 17% of revenue, and CVS Health remains a critical concentration risk. With core pharmaceutical distribution margins of just 1.10%, a small pricing miscalculation or additional customer loss can eliminate profitability. Structural generic drug deflation compresses margins further. The specialty care pivot is strategically correct but carries substantial integration risk, and these businesses are smaller than the core distribution operation. Vertical integration by customers and potential disruption from Amazon represent long-term competitive threats.
Bottom Line
Cardinal Health is navigating a structural transition with remarkable resilience. The company absorbed a $38.1 billion revenue loss—17% of annual sales—while improving profitability and raising earnings guidance, demonstrating that revenue quality matters more than revenue quantity in pharmaceutical wholesale. The fiscal 2025 results showed 83% growth in GAAP operating earnings and 15% growth in non-GAAP operating earnings despite the revenue decline. The specialty care acquisition strategy (oncology, gastroenterology, diabetes, urology) represents a genuine pivot toward higher-margin, recurring revenues. But the core business remains a commodity distribution operation with 1% margins, and the success of the transformation depends on integrating physician practice management businesses that require different capabilities than pharmaceutical logistics. Cardinal Health is either the healthcare sector's most undervalued turnaround story or a company permanently trapped in a low-margin business model—and the 2025-2027 execution of its specialty services strategy will determine which.
